Explore ADB-CHMINACA | TiHKAL · info

Exploring ADB-CHMINACA. To explore a different substance…

Names

ADB-CHMINACA
ADMB-CHMINACA
MAB-CHMINACA

IUPAC name

N-[(2S)-1-Amino-3,3-dimethyl-1-oxobutan-2-yl]-1-(cyclohexylmethyl)-1H-indazole-3-carboxamide

ID 4508 · Formula C₂₁H₃₀N₄O₂ · Molecular weight 370.489

Tags Cannabinoid

InChI InChI=1S/C21H30N4O2/c1-21(2,3)18(19(22)26)23-20(27)17-15-11-7-8-12-16(15)25(24-17)13-14-9-5-4-6-10-14/h7-8,11-12,14,18H,4-6,9-10,13H2,1-3H3,(H2,22,26)(H,23,27)/t18-/m1/s1

InChI Key ZWCCSIUBHCZKOY-GOSISDBHSA-N This stereoisomer Any stereoisomer

SMILES O=C(c1nn(c2c1cccc2)CC1CCCCC1)N[C@@H](C(C)(C)C)C(=O)N

ChemSpider 48059556
PubChem 68894304
Wikidata Q27289262
Wikipedia ADB-CHMINACA
Project Response ADB-CHMINACA (1380-15)
forensicdrugreview.com MAB-CHMINACA
swgdrug.org MAB-CHMINACA
aipsin.com ADB-CHMINACA (Iss. 3, Jun-Sep 2019: VII-8)

EMCDDA. New drugs in Europe, 2015, European Monitoring Centre for Drugs and Drug Addiction, Lisbon, 1 May 2016. 1.0 MB. #39

EMCDDA. New drugs in Europe, 2014, European Monitoring Centre for Drugs and Drug Addiction, Lisbon, 1 Jul 2015. 879 kB.

Kaizaki-Mitsumoto, A; Noguchi, N; Yamaguchi, S; Odanaka, Y; Matsubayashi, S; Kumamoto, H; Fukuhara, K; Funada, M; Wada, K; Numazawa, S. Three 25-NBOMe-type drugs, three other phenethylamine-type drugs (25I-NBMD, RH34, and escaline), eight cathinone derivatives, and a phencyclidine analog MMXE, newly identified in ingredients of drug products before they were sold on the drug market. Forensic Toxicol., 1 Jan 2016, 34 (1), 108–114. 854 kB. https://doi.org/10.1007/s11419-015-0293-6

Dunne, SJ; Rosengren-Holmberg, JP. Quantification of synthetic cannabinoids in herbal smoking blends using NMR. Drug Test. Anal., 1 May 2017, 9 (5), 734-743. 988 kB. https://doi.org/10.1002/dta.2032

Hess, C; Murach, J; Krueger, L; Scharrenbroch, L; Unger, M; Madea, B; Sydow, K. Simultaneous detection of 93 synthetic cannabinoids by liquid chromatography-tandem mass spectrometry and retrospective application to real forensic samples. Drug Test. Anal., 1 May 2017, 9 (5), 721-733. 267 kB. https://doi.org/10.1002/dta.2030 #MAB-CHMINACA LC,MS

Abbate, V; Schwenk, M; Presley, BC; Uchiyama, N. The ongoing challenge of novel psychoactive drugs of abuse. Part I. Synthetic cannabinoids (IUPAC Technical Report). Pure Appl. Chem., 28 Aug 2018, 90 (8), 1255–1282. 1.0 MB. https://doi.org/10.1515/pac-2017-0605 #8. ADB-CHMINACA

EMCDDA. Report on the risk assessment of N-(1-Amino-3,3-dimethyl-1-oxobutan-2-yl)-1-(cyclohexylmethyl)-1H-indazole-3-carboxamide (ADB-CHMINACA), European Monitoring Centre for Drugs and Drug Addiction, Lisbon, 1 May 2018. 1.1 MB. #ADB-CHMINACA

Banister, SD; Connor, M. The chemistry and pharmacology of synthetic cannabinoid receptor agonist new psychoactive substances: Evolution. In New Psychoactive Substances: Pharmacology, Clinical, Forensic and Analytical Toxicology; Maurer, HH; Brandt, SD, Eds., Springer, Berlin, Heidelberg, 1 Jan 2018; pp 191-226. 1.2 MB. https://doi.org/10.1007/164_2018_144 #46

Kronstrand, R; Guerrieri, D; Vikingsson, S; Wohlfarth, A; Gréen, H. Fatal poisonings associated with new psychoactive substances. In New Psychoactive Substances: Pharmacology, Clinical, Forensic and Analytical Toxicology; Maurer, HH; Brandt, SD, Eds., Springer, Berlin, Heidelberg, 1 Jan 2018; pp 495–541. 477 kB. https://doi.org/10.1007/164_2018_110 #ADB-CHMINACA

Kraemer, M; Boehmer, A; Madea, B; Maas, A. Death cases involving certain new psychoactive substances: A review of the literature. Forensic Sci. Int., 1 May 2019, 298, 186–267. 6.7 MB. https://doi.org/10.1016/j.forsciint.2019.02.021 #MAB-CHMINACA

Kikura-Hanajiri, R. New designer drugs in japan. In Neuropathology of Drug Addictions and Substance Misuse; Preedy, VR, Ed., Academic Press, 1 Jan 2016; pp 1055–1065. 682 kB. https://doi.org/10.1016/B978-0-12-800212-4.00097-2 #ADB-CHMINACA

Cannaert, A; Sparkes, E; Pike, E; Luo, JL; Fang, A; Kevin, RC; Ellison, R; Gerona, R; Banister, SD; Stove, CP. Synthesis and in vitro cannabinoid receptor 1 activity of recently detected synthetic cannabinoids 4F-MDMB-BICA, 5F-MPP-PICA, MMB-4en-PICA, CUMYL-CBMICA, ADB-BINACA, APP-BINACA, 4F-MDMB-BINACA, MDMB-4en-PINACA, A-CHMINACA, 5F-AB-P7AICA, 5F-MDMB-P7AICA, and 5F-AP7AICA. ACS Chem. Neurosci., 16 Dec 2020, 11 (24), 4434–4446. 3.7 MB. https://doi.org/10.1021/acschemneuro.0c00644 #10b MS,NMR,IR,TLC

Wouters, E; Mogler, L; Cannaert, A; Auwärter, V; Stove, C. Functional evaluation of carboxy metabolites of synthetic cannabinoid receptor agonists featuring scaffolds based on L‐valine or L‐ tert ‐leucine. Drug Test. Anal., 1 Aug 2019, 11 (8), 1183–1191. 1.4 MB. https://doi.org/10.1002/dta.2607 #11

Kevin, RC; Mirlohi, S; Manning, JJ; Boyd, R; Cairns, EA; Ametovski, A; Lai, F; Luo, JL; Jorgensen, W; Ellison, R; Gerona, RR; Hibbs, DE; McGregor, IS; Glass, M; Connor, M; Bladen, C; Zamponi, GW; Banister, SD. Putative synthetic cannabinoids MEPIRAPIM, 5F-BEPIRAPIM (NNL-2), and their analogues are T-type calcium channel (Ca_V3) inhibitors. ACS Chem. Neurosci., 4 May 2022, 13 (9), 1395–1409. 4.5 MB. https://doi.org/10.1021/acschemneuro.1c00822 #4 MS,NMR

WO 2009/106980 #15

N-{3,5-Dimethyl-1-[2-(1H-pyrazol-1-yl)ethyl]piperidin-4-yl}-2-methoxy-N-phenylacetamide

7 Dec 2019 · · Isomer Design